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Effects of Encapsulated BDNF-Producing Fibroblasts on
Dorsal Root Ganglia Neurite Growth
Nicola L. Francis, Margaret A. Wheatley
School of Biomedical Engineering, Science & Health Systems, Drexel University, Philadelphia PA, 19104
Fibroblasts genetically engineered to produce Brain-Derived
Neurotrophic Factor (FB/BDNF) have been shown to promote axonal
regeneration in the injured spinal cord of an immune-suppressed rat.
To avoid immune suppression and protect the cells from the host
immune response, FB/BDNF were encapsulated in various alginate
gels. BDNF secreted by the fibroblasts was able to diffuse out of the
alginate and remain bioactive, stimulating significantly more neurite
growth than alginate without encapsulated fibroblasts. A BDNF
concentration gradient was also shown to guide DRG neurite growth
towards the source. These positive neurotrophic effects show
promise as a repair strategy for spinal cord injury.
•CaCl2 fibers and
CaCO3-GDL discs
promoted significantly
more neurite growth
than CaSO4 discs
(p<0.001)
•CaCl2 and CaCO3-GDL
alginates are suitable for
use as a DRG growth
substrate
•Choosing between the
two depends on needs:
gelation speed,
uniformity, desired
shape
To develop a graft suitable for implantation into the injured spinal cord that will:
• Provide a favorable substrate for neuronal adhesion and growth
• Facilitate the use of ex vivo gene therapy without host immune suppression
• Promote the growth and directional guidance of neurons with a concentration gradient of
growth factors
•Evaluate effects of FB/NT-3 (neurotrophin-3) on DRG neurite growth
•Evaluate synergy of FB/BDNF and FB/NT-3 on DRG neurite growth
•Vary concentration gradients in alginate to find optimum concentration for
FB survival and DRG growth
•Quantify release of BDNF and compare to release from YIGSR-coated
alginate
•In vivo testing of alginate graft
•BDNF secreted by fibroblasts able to diffuse out of alginate and remain
bioactive, stimulating neurite growth
•Alginate-encapsulated FB/BDNF (mean neurite length = 306.4 ± 60.72
_m) promoted significantly more DRG neurite growth than alginate
without FB/BDNF (mean neurite length = 223.0 ± 65.46 _m)
•Alginate not containing FB/BDNF has neurotrophic properties
•No neurite growth after 24 h suggests an inhibitory interaction between
CaSO4 alginate, encapsulated FB/BDNF, and DRGs
•CaCl2 alginate and CaCO3-GDL alginate stimulated significantly more
neurite outgrowth than CaSO4 alginate
•BDNF concentration gradient guided growth of DRG neurite towards the
source
Spinal cord injury (SCI):
• Affects nearly 250,000 people in the U.S.
• Approximately 11,000 new cases every year
• Can lead to loss of sensation and motor function; chronic pain;
spasticity; and bowel, bladder, and sexual dysfunction
• Effects caused by death of neurons that cannot be replaced, poor
regenerative capacity of surviving neurons, damaged CNS 
environment is inhospitable for growth
• Ex vivo gene therapy (genetically engineering cells to express a
transgene) is a promising strategy for SCI repair, but immune 
suppression is needed
• Method needed to provide benefits of ex vivo gene therapy 
without suppressing immune system
Alginate:
• Linear polysaccharide derived from seaweed
• Consists of 1,4-linked _-L-guluronic acid  and _-D-mannuronic
acid monomers
• FDA ‘Generally Recognized as Safe’ Status
• Nontoxic, biocompatible, easy to process into various shapes,
capable of immobilizing biomolecules (such as BDNF-producing
fibroblasts)
• Coating with polypeptides will control porosity, stability, and
create an isolation barrier from the immune system
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Discs:
•BDNF-producing fibroblasts (FB/BDNF) resuspended in
alginate
•Alginate mixed with CaCO3-GDL solutions or CaSO4 slurry
•Mixture shaken and poured into culture plates
•Discs coated with poly-L-ornithine (PLO) and laminin
Fibers:
•FB/BDNF resuspended in alginate
•Alginate injected into CaCl2 solution
•Fibers coated with PLO and laminin
•Dorsal root ganglia (DRGs) removed from 10-day old chick
embryos
•DRGs cultured on alginate and observed for up to 72 hours
FB/BDNF encapsulated in alginate (100x)
DRG Neurite Extension with
Alginate Fibers
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DRG Neurite Extension with
Various Alginate Gels
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BDNF CONCENTRATION GRADIENT
•Concentration gradient formed by
covering DRGs and FB/BDNF alginate
fibers with 1% agarose
•Agarose slowed the diffusion rate of
BDNF and more closely resembled an in
vivo environment
•DRGs sprouted neurites under agarose
•Neurites grew and turned towards
alginate fibers
•FB/BDNF alginate fibers promoted greater
directional guidance of neurites than plain
alginate fibers (p<0.05)
100µm
100µm
Growth of DRG neurites towards source of BDNF (100x)
All photos: 100x
•Alginate with FB/BDNF promoted
significantly more neurite growth
than plain alginate fibers (not
containing FB/BDNF) (p<0.05)
•Statistically similar neurite lengths
with supplemental recombinant
BDNF (positive control #1), medium
from FB/BDNF in culture (positive
control #2), and alginate
encapsulated FB/BDNF (p>0.05)
